EBS insider files Form 144 to sell 30,608 shares valued at $306,080

Rhea-AI Filing Summary

Emergent BioSolutions filed a Form 144 reporting a proposed sale of 30,608 common shares with an aggregate market value of $306,080.00, which are to be sold through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 10/07/2025. The filing shows the shares were received as restricted stock in multiple grants from the issuer between 04/07/2023 and 12/08/2024, with the largest single grant listed as 26,779 shares on 12/08/2024. The filer represents no undisclosed material nonpublic information and reports no sales of issuer securities in the past three months.

Positive

• Clear disclosure of the proposed sale amount: 30,608 shares valued at $306,080.00
• Securities acquired as restricted stock from the issuer across dated grants, showing legitimate insider holdings
• No sales in the prior three months reported, indicating this is not part of an ongoing rapid-disposition pattern

Negative

• Sale represents insider liquidity, which some investors may view neutrally or unfavorably depending on timing
• Proposed sale date is several months out (10/07/2025), creating uncertainty until execution is reported

Insights

Insider Transactions Analyst

TL;DR: An insider plans a modest sale of restricted shares totaling $306,080, sourced from recent restricted grants.

The filing indicates the sale is small relative to total shares outstanding (30,608 versus 53,351,099 outstanding), and the securities were acquired as restricted stock across five grant dates from 04/07/2023 to 12/08/2024. Sales routed through Morgan Stanley Smith Barney LLC on the NYSE imply a standard brokerage execution.

Key dependencies include the exact execution date around 10/07/2025 and market price at sale; monitor the transaction report for actual sale timing and proceeds settlement within the normal Form 144 reporting window.

Corporate Governance Specialist

TL;DR: The filer affirms no material nonpublic information and shows no recent sales, suggesting routine insider liquidity rather than unusual activity.

The disclosure lists multiple restricted-stock acquisitions from the issuer and no aggregated sales in the prior three months, aligning with standard Rule 144 notice practice when insiders sell vested restricted shares. The representation about lack of material undisclosed information is a required attestation on the form.

Watch for the subsequent Form 4 or broker-reported trades after 10/07/2025 to confirm execution and any pattern of sales that could affect perception of insider confidence.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	30608	306080.00	53351099	10/07/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2024	Restricted Stock	ISSUER			901	03/01/2024	Not Applicable
Common	04/07/2023	Restricted Stock	ISSUER			1491	04/07/2023	Not Applicable
Common	06/08/2024	Restricted Stock	ISSUER			51	06/08/2024	Not Applicable
Common	12/08/2024	Restricted Stock	ISSUER			26779	12/08/2024	Not Applicable
Common	04/07/2024	Restricted Stock	ISSUER			1386	04/07/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Emergent BioSolutions (EBS) report in this Form 144?

The filing reports a proposed sale of 30,608 common shares with an aggregate market value of $306,080.00, to be executed through Morgan Stanley Smith Barney LLC on the NYSE around 10/07/2025.

How were the shares being sold acquired by the filer?

The shares were acquired as restricted stock in multiple grants from the issuer on dates between 04/07/2023 and 12/08/2024, with the largest grant of 26,779 shares on 12/08/2024.

Does the filing report recent sales of EBS securities by the filer?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months.

What does the filer represent about material nonpublic information?

By signing the notice, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

Through which broker will the sale be executed?

The broker named is Morgan Stanley Smith Barney LLC, address listed as 1 New York Plaza, New York, NY, for execution on the NYSE.